Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
作者
Robert Leonard,Joyce O’Shaughnessy,Svetislava J. Vukelja,Vera Gorbounova,C.A. Chan-Navarro,D Maraninchi,N. Barak-Wigler,JJ McKendrick,W G Harker,A.S. Bexon,Chris Twelves
出处
期刊:Annals of Oncology [Elsevier BV] 日期:2006-09-01卷期号:17 (9): 1379-1385被引量:52